SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '1rjb'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1FMO_E_ADNE351_1 (CAMP-DEPENDENT PROTEIN KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 GLY A 617 VAL A 624 ALA A 642 VAL A 675 ASN A 816 LEU A 818	None	0.58A	1fmoE-1rjbA: 20.2	1fmoE-1rjbA: 25.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1FMO_E_ADNE351_1 (CAMP-DEPENDENT PROTEIN KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 VAL A 624 ALA A 642 VAL A 675 ASN A 816 LEU A 818 ASP A 829	None	0.62A	1fmoE-1rjbA: 20.2	1fmoE-1rjbA: 25.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1MUO_A_ADNA1_1 (AURORA-RELATED KINASE 1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 9	LEU A 616 GLY A 617 VAL A 624 ALA A 642 TYR A 693 LEU A 818	None	0.67A	1muoA-1rjbA: 17.2	1muoA-1rjbA: 27.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1MXG_A_ACRA443_1 (ALPHA AMYLASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	4 / 8	SER A 941 THR A 940 ASN A 938 LYS A 868	None	1.20A	1mxgA-1rjbA: undetectable	1mxgA-1rjbA: 22.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_A_STIA3_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	LEU A 616 VAL A 624 ALA A 642 GLU A 661 VAL A 675 LEU A 818	None	0.67A	1opjA-1rjbA: 32.5	1opjA-1rjbA: 35.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_B_STIB4_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	VAL A 624 ALA A 642 GLU A 661 VAL A 675 GLY A 697 ASP A 829	None	0.83A	1opjB-1rjbA: 32.4	1opjB-1rjbA: 35.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1SGU_B_MK1B2632_1 (POL POLYPROTEIN)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 8	ALA A 792 ILE A 921 GLY A 875 ILE A 876 PRO A 911	None	1.19A	1sguA-1rjbA: undetectable	1sguA-1rjbA: 14.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1SH9_B_RITB301_1 (POL POLYPROTEIN)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 8	ALA A 792 ILE A 918 ILE A 921 GLY A 875 ILE A 876 PRO A 911	None	1.11A	1sh9A-1rjbA: undetectable	1sh9A-1rjbA: 14.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T46_A_STIA3_1 (HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	9 / 12	LEU A 616 VAL A 624 ALA A 642 LYS A 644 GLU A 661 VAL A 675 GLY A 697 LEU A 818 ASP A 829	None	0.64A	1t46A-1rjbA: 40.4	1t46A-1rjbA: 58.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T46_A_STIA3_2 (HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	4 / 7	TYR A 693 CYH A 694 CYH A 807 CYH A 828	None	0.48A	1t46A-1rjbA: 40.4	1t46A-1rjbA: 58.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 12	ALA A 642 GLU A 661 CYH A 694 LEU A 802 HIS A 809	None	0.45A	1uwhA-1rjbA: 28.1	1uwhA-1rjbA: 26.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	ALA A 642 LYS A 644 GLU A 661 CYH A 694 LEU A 802 HIS A 809	None	0.72A	1uwhB-1rjbA: 27.8	1uwhB-1rjbA: 26.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	VAL A 624 ALA A 642 GLU A 661 CYH A 694 LEU A 802 HIS A 809	None	0.51A	1uwjA-1rjbA: 7.7	1uwjA-1rjbA: 26.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	VAL A 624 ALA A 642 GLU A 661 CYH A 694 LEU A 802 HIS A 809	None	0.51A	1uwjB-1rjbA: 7.7	1uwjB-1rjbA: 26.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EUF_B_LQQB401_1 (CELL DIVISION PROTEIN KINASE 6)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 12	VAL A 624 LYS A 644 VAL A 675 PHE A 691 ASP A 698 ASN A 816 LEU A 818 ASP A 829	None	0.91A	2eufB-1rjbA: 22.4	2eufB-1rjbA: 26.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_A_STIA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	VAL A 624 ALA A 642 GLU A 661 GLY A 697 LEU A 818 ASP A 829	None	0.76A	2hyyA-1rjbA: 33.5	2hyyA-1rjbA: 37.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_B_STIB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	VAL A 624 ALA A 642 GLU A 661 GLY A 697 LEU A 818 ASP A 829	None	0.78A	2hyyB-1rjbA: 33.8	2hyyB-1rjbA: 37.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2O4N_A_TPVA300_1 (PROTEASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 12	ALA A 792 ILE A 918 ILE A 921 GLY A 875 PRO A 911	None	0.93A	2o4nA-1rjbA: undetectable	2o4nA-1rjbA: 14.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2O4P_A_TPVA300_1 (PROTEASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 11	ALA A 792 ILE A 921 GLY A 875 ILE A 876 PRO A 911	None	1.09A	2o4pA-1rjbA: undetectable	2o4pA-1rjbA: 15.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2YFX_A_VGHA9000_1 (TYROSINE-PROTEIN KINASE RECEPTOR)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	4 / 8	LEU A 616 ALA A 642 GLY A 697 LEU A 818	None	0.58A	2yfxA-1rjbA: 29.3	2yfxA-1rjbA: 36.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3C7Q_A_XINA1172_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	9 / 12	LEU A 616 GLY A 617 ALA A 642 LYS A 644 VAL A 675 CYH A 694 GLY A 697 LEU A 818 CYH A 828	None	0.60A	3c7qA-1rjbA: 35.2	3c7qA-1rjbA: 51.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3EL4_A_ROCA100_2 (PROTEASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 9	ALA A 792 ILE A 921 GLY A 875 ILE A 876 PRO A 911	None	1.25A	3el4B-1rjbA: undetectable	3el4B-1rjbA: 14.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3EL5_B_1UNB201_1 (PROTEASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 10	ALA A 792 ILE A 921 GLY A 875 ILE A 876 PRO A 911	None	1.17A	3el5A-1rjbA: undetectable	3el5A-1rjbA: 15.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3FUP_B_MI1B1_1 (TYROSINE-PROTEIN KINASE JAK2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 GLY A 617 VAL A 624 ALA A 642 VAL A 675 TYR A 693 LEU A 818	None	0.53A	3fupB-1rjbA: 27.7	3fupB-1rjbA: 31.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G0E_A_B49A9000_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	10 / 11	LEU A 616 VAL A 624 ALA A 642 VAL A 675 TYR A 693 CYH A 694 GLY A 697 LEU A 818 CYH A 828 ALA A 833	None	0.54A	3g0eA-1rjbA: 41.8	3g0eA-1rjbA: 56.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G0F_A_B49A9001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	9 / 11	LEU A 616 VAL A 624 ALA A 642 TYR A 693 CYH A 694 GLY A 697 ASP A 698 LEU A 818 CYH A 828	None	0.55A	3g0fA-1rjbA: 38.5	3g0fA-1rjbA: 56.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G0F_B_B49B9001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 10	LEU A 616 VAL A 624 ALA A 642 TYR A 693 CYH A 694 GLY A 697 LEU A 818 CYH A 828	None	0.48A	3g0fB-1rjbA: 38.8	3g0fB-1rjbA: 56.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G5D_B_1N1B1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	9 / 12	LEU A 616 VAL A 624 ALA A 642 LYS A 644 GLU A 661 VAL A 675 TYR A 693 GLY A 697 LEU A 818	None	0.94A	3g5dB-1rjbA: 29.7	3g5dB-1rjbA: 36.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GVU_A_STIA1001_1 (TYROSINE-PROTEIN KINASE ABL2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 VAL A 624 ALA A 642 GLU A 661 VAL A 675 LEU A 818 ASP A 829	None	0.82A	3gvuA-1rjbA: 32.1	3gvuA-1rjbA: 38.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_A_0LIA1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 12	ALA A 642 GLU A 661 HIS A 809 LEU A 818 ASP A 829	None	0.68A	3ik3A-1rjbA: 32.0	3ik3A-1rjbA: 37.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_A_STIA2_1 (TYROSINE-PROTEIN KINASE ABL1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	VAL A 624 ALA A 642 GLU A 661 GLY A 697 LEU A 818 ASP A 829	None	0.76A	3k5vA-1rjbA: 32.6	3k5vA-1rjbA: 35.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3KO0_C_TFPC201_1 (PROTEIN S100-A4)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 9	PHE A 898 GLY A 891 ILE A 876 MET A 855 PHE A 861	None	1.49A	3ko0A-1rjbA: undetectable 3ko0C-1rjbA: undetectable	3ko0A-1rjbA: 16.67 3ko0C-1rjbA: 16.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 VAL A 624 ALA A 642 GLU A 661 GLY A 697 LEU A 818 ASP A 829	None	0.79A	3ms9B-1rjbA: 33.4	3ms9B-1rjbA: 35.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_D_STID1_1 (TYROSINE-PROTEIN KINASE ABL1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	LEU A 616 ALA A 642 GLU A 661 GLY A 697 LEU A 818 ASP A 829	None	0.76A	3mssD-1rjbA: 33.5	3mssD-1rjbA: 35.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3NUO_B_478B478_1 (PROTEASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 9	ALA A 792 ILE A 921 GLY A 875 ILE A 876 PRO A 911	None	1.10A	3nuoA-1rjbA: undetectable	3nuoA-1rjbA: 14.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OCT_A_1N1A663_1 (TYROSINE-PROTEIN KINASE BTK)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 12	LEU A 616 VAL A 624 ALA A 642 LYS A 644 VAL A 675 TYR A 693 GLY A 697 LEU A 818	None	0.71A	3octA-1rjbA: 29.8	3octA-1rjbA: 36.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OCT_A_1N1A663_1 (TYROSINE-PROTEIN KINASE BTK)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 12	LEU A 616 VAL A 624 LYS A 644 MET A 665 VAL A 675 TYR A 693 GLY A 697 LEU A 818	None	1.00A	3octA-1rjbA: 29.8	3octA-1rjbA: 36.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OEZ_A_STIA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	ALA A 642 GLU A 661 VAL A 675 TYR A 693 GLY A 697 LEU A 818 ASP A 829	None	0.71A	3oezA-1rjbA: 30.8	3oezA-1rjbA: 35.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	ALA A 642 GLU A 661 VAL A 675 GLY A 697 HIS A 809 ASP A 829	None	0.72A	3oxzA-1rjbA: 31.7	3oxzA-1rjbA: 37.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_B_STIB4_1 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 VAL A 624 ALA A 642 GLU A 661 VAL A 675 LEU A 818 ASP A 829	None	0.82A	3pyyB-1rjbA: 31.1	3pyyB-1rjbA: 35.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3QLG_B_1N1B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 12	LEU A 616 VAL A 624 ALA A 642 GLU A 661 VAL A 675 TYR A 693 GLY A 697 LEU A 818	None	0.81A	3qlgB-1rjbA: 29.7	3qlgB-1rjbA: 35.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3RGF_A_BAXA465_1 (CYCLIN-DEPENDENT KINASE 8)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	VAL A 624 ALA A 642 GLU A 661 PHE A 691 TYR A 693 LEU A 802 HIS A 809	None	0.82A	3rgfA-1rjbA: 20.3	3rgfA-1rjbA: 27.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3RGF_A_BAXA465_2 (CYCLIN-DEPENDENT KINASE 8)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	4 / 7	LEU A 818 VAL A 675 LEU A 668 ASP A 829	None	0.82A	3rgfA-1rjbA: 20.3	3rgfA-1rjbA: 27.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_A_1N1A1_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 VAL A 624 ALA A 642 VAL A 675 TYR A 693 GLY A 697 LEU A 818	None	0.52A	3sxrA-1rjbA: 29.1	3sxrA-1rjbA: 36.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_B_1N1B2_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 VAL A 624 ALA A 642 VAL A 675 TYR A 693 GLY A 697 LEU A 818	None	0.53A	3sxrB-1rjbA: 28.9	3sxrB-1rjbA: 36.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3TI1_A_B49A299_1 (CYCLIN-DEPENDENT KINASE 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 9	ALA A 642 VAL A 675 PHE A 691 ASP A 698 LEU A 818	None	0.71A	3ti1A-1rjbA: 21.3	3ti1A-1rjbA: 26.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3U7S_A_017A201_2 (POL POLYPROTEIN)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 9	ALA A 792 ILE A 921 GLY A 875 ILE A 876 PRO A 911	None	1.16A	3u7sB-1rjbA: undetectable	3u7sB-1rjbA: 15.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3WZD_A_LEVA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 GLY A 617 VAL A 624 ALA A 642 GLU A 661 CYH A 694 CYH A 828	None	0.87A	3wzdA-1rjbA: 33.7	3wzdA-1rjbA: 48.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3WZD_A_LEVA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 VAL A 624 ALA A 642 GLU A 661 CYH A 694 GLY A 697 CYH A 828	None	0.58A	3wzdA-1rjbA: 33.7	3wzdA-1rjbA: 48.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3WZE_A_BAXA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 12	LEU A 616 VAL A 624 ALA A 642 LYS A 644 GLU A 661 GLY A 697 LEU A 802 HIS A 809	None	0.60A	3wzeA-1rjbA: 40.1	3wzeA-1rjbA: 48.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3WZE_A_BAXA1201_2 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 8	VAL A 675 CYH A 694 LEU A 818 ILE A 827 CYH A 828 ASP A 829	None	0.66A	3wzeA-1rjbA: 40.1	3wzeA-1rjbA: 48.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3WZE_A_BAXA1201_2 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 8	VAL A 675 ILE A 827 CYH A 828 ASP A 829 PHE A 830	None	0.83A	3wzeA-1rjbA: 40.1	3wzeA-1rjbA: 48.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ZOS_A_0LIA1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 12	LEU A 616 ALA A 642 LYS A 644 GLU A 661 HIS A 809 ARG A 810 LEU A 818 ASP A 829	None	0.87A	3zosA-1rjbA: 32.8	3zosA-1rjbA: 32.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ZOS_A_0LIA1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 12	LEU A 616 ALA A 642 LYS A 644 GLU A 661 LEU A 802 HIS A 809 LEU A 818 ASP A 829	None	0.73A	3zosA-1rjbA: 32.8	3zosA-1rjbA: 32.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ZOS_B_0LIB1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	ALA A 642 LYS A 644 GLU A 661 LEU A 802 HIS A 809 LEU A 818 ASP A 829	None	0.72A	3zosB-1rjbA: 33.0	3zosB-1rjbA: 32.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	9 / 12	LEU A 616 VAL A 624 ALA A 642 LYS A 644 GLU A 661 VAL A 675 GLY A 697 LEU A 818 CYH A 828	None	0.53A	4ag8A-1rjbA: 40.2	4ag8A-1rjbA: 48.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 12	LEU A 616 VAL A 624 ALA A 642 LYS A 644 GLU A 661 GLY A 697 LEU A 818 CYH A 828	None	0.53A	4agcA-1rjbA: 42.2	4agcA-1rjbA: 47.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 11	LEU A 616 ALA A 642 LYS A 644 VAL A 675 CYH A 694 GLY A 697 LEU A 818 CYH A 828	None	0.65A	4agdA-1rjbA: 41.1	4agdA-1rjbA: 47.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 11	LYS A 644 VAL A 675 GLY A 697 LEU A 818 CYH A 828 PHE A 830	None	1.26A	4agdA-1rjbA: 41.1	4agdA-1rjbA: 47.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ASD_A_BAXA1500_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 12	LEU A 616 VAL A 624 ALA A 642 LYS A 644 GLU A 661 GLY A 697 LEU A 802 HIS A 809	None	0.53A	4asdA-1rjbA: 40.6	4asdA-1rjbA: 47.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ASD_A_BAXA1500_2 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 6	VAL A 675 CYH A 694 LEU A 818 ILE A 827 CYH A 828	None	0.55A	4asdA-1rjbA: 40.6	4asdA-1rjbA: 47.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4C8B_A_0LIA1000_2 (RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	4 / 5	VAL A 624 ILE A 674 TYR A 693 ILE A 827	None	0.45A	4c8bA-1rjbA: 25.5	4c8bA-1rjbA: 25.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4C8B_B_0LIB1000_1 (RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	ALA A 642 LYS A 644 GLU A 661 ILE A 674 HIS A 809 LEU A 818 ASP A 829	None	0.85A	4c8bB-1rjbA: 25.3	4c8bB-1rjbA: 25.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4CKI_A_ADNA2022_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 11	LEU A 616 GLY A 617 VAL A 624 ALA A 642 TYR A 693 GLY A 697 LEU A 818	None	0.51A	4ckiA-1rjbA: 30.8	4ckiA-1rjbA: 42.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4CKI_A_ADNA2022_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 11	LEU A 616 GLY A 831 ALA A 642 TYR A 693 GLY A 697 LEU A 818	None	0.67A	4ckiA-1rjbA: 30.8	4ckiA-1rjbA: 42.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4CKJ_A_ADNA2014_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 10	LEU A 616 GLY A 617 GLY A 619 VAL A 624 ALA A 642 TYR A 693 LEU A 818	None	0.55A	4ckjA-1rjbA: 31.5	4ckjA-1rjbA: 43.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4IAA_A_RTZA401_1 (SERINE/THREONINE-PRO TEIN KINASE PIM-1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 11	VAL A 624 ALA A 642 LYS A 644 ASP A 698 LEU A 818 ASP A 829	None	0.83A	4iaaA-1rjbA: 20.4	4iaaA-1rjbA: 24.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4L9I_A_8PRA601_1 (RHODOPSIN KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	4 / 7	VAL A 624 ALA A 642 ASP A 698 LEU A 818	None	0.56A	4l9iA-1rjbA: 7.8	4l9iA-1rjbA: 22.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4L9I_B_8PRB601_1 (RHODOPSIN KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 8	VAL A 624 ALA A 642 LYS A 644 ASP A 698 LEU A 818	None	0.78A	4l9iB-1rjbA: 20.2	4l9iB-1rjbA: 22.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MKC_A_4MKA1503_1 (ALK TYROSINE KINASE RECEPTOR)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 VAL A 624 ALA A 642 LYS A 644 GLY A 697 ASP A 698 LEU A 818	None	0.55A	4mkcA-1rjbA: 29.5	4mkcA-1rjbA: 36.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4O0W_A_ADNA501_1 (AURORA KINASE A)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 6	LEU A 616 GLY A 617 VAL A 624 ALA A 642 LEU A 818	None	0.52A	4o0wA-1rjbA: 22.8	4o0wA-1rjbA: 26.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OGR_E_ADNE401_1 (CYCLIN-DEPENDENT KINASE 9)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 7	ALA A 642 CYH A 694 ASP A 698 ASN A 816 LEU A 818 ASP A 829	None	0.88A	4ogrE-1rjbA: 21.1	4ogrE-1rjbA: 27.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OGR_E_ADNE401_1 (CYCLIN-DEPENDENT KINASE 9)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 7	GLY A 617 ALA A 642 CYH A 694 ASP A 698 LEU A 818	None	0.94A	4ogrE-1rjbA: 21.1	4ogrE-1rjbA: 27.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OGR_I_ADNI401_1 (CYCLIN-DEPENDENT KINASE 9)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 9	GLY A 831 ALA A 642 CYH A 694 ASP A 698 ASN A 816 LEU A 818	None	0.96A	4ogrI-1rjbA: 21.0	4ogrI-1rjbA: 27.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OGR_I_ADNI401_1 (CYCLIN-DEPENDENT KINASE 9)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 9	GLY A 831 CYH A 694 ASP A 698 ASN A 816 LEU A 818 ASP A 829	None	1.05A	4ogrI-1rjbA: 21.0	4ogrI-1rjbA: 27.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OGR_I_ADNI401_1 (CYCLIN-DEPENDENT KINASE 9)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 9	VAL A 624 ALA A 642 CYH A 694 ASP A 698 ASN A 816 LEU A 818	None	0.76A	4ogrI-1rjbA: 21.0	4ogrI-1rjbA: 27.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QRC_A_0LIA802_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	4 / 8	LEU A 616 VAL A 624 HIS A 809 LEU A 818	None	0.37A	4qrcA-1rjbA: 33.7	4qrcA-1rjbA: 43.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4R7I_A_STIA1001_1 (MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	VAL A 624 ALA A 642 LYS A 644 GLU A 661 CYH A 694 CYH A 807 LEU A 818	None	0.61A	4r7iA-1rjbA: 39.9	4r7iA-1rjbA: 55.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4R7I_A_STIA1001_1 (MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	VAL A 624 ALA A 642 LYS A 644 GLU A 661 CYH A 694 LEU A 818 ASP A 829	None	0.59A	4r7iA-1rjbA: 39.9	4r7iA-1rjbA: 55.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_A_AXIA601_1 (TYROSINE-PROTEIN KINASE ABL1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 12	LEU A 616 VAL A 624 ALA A 642 LYS A 644 GLY A 697 ASN A 816 LEU A 818 ASP A 829	None	0.79A	4twpA-1rjbA: 30.5	4twpA-1rjbA: 37.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TYJ_A_0LIA801_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	4 / 6	LEU A 616 VAL A 624 ILE A 674 ILE A 827	None	0.35A	4tyjA-1rjbA: 33.4	4tyjA-1rjbA: 43.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U0I_A_0LIA1001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 10	LEU A 616 VAL A 624 GLU A 661 LEU A 668 ILE A 674 VAL A 675 TYR A 693 ILE A 827	None	0.78A	4u0iA-1rjbA: 39.8	4u0iA-1rjbA: 55.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U0I_A_0LIA1001_2 (MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 12	ALA A 642 LYS A 644 CYH A 694 GLY A 697 HIS A 809 LEU A 818 CYH A 828 ASP A 829	None	0.64A	4u0iA-1rjbA: 39.8	4u0iA-1rjbA: 55.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 11	LEU A 616 VAL A 624 ALA A 642 TYR A 693 GLY A 697 ASN A 816 LEU A 818 ASP A 829	None	0.70A	4u5jA-1rjbA: 30.3	4u5jA-1rjbA: 36.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 9	LEU A 616 VAL A 624 ALA A 642 TYR A 693 GLY A 697 LEU A 818 ASP A 829	None	0.93A	4u5jB-1rjbA: 29.9	4u5jB-1rjbA: 36.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4UXQ_A_0LIA1752_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	LEU A 616 ALA A 642 GLU A 661 LEU A 802 HIS A 809 LEU A 818	None	0.62A	4uxqA-1rjbA: 34.2	4uxqA-1rjbA: 43.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_A_0LIA1776_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	ALA A 642 GLU A 661 MET A 664 LEU A 802 HIS A 809 ASP A 829	None	0.98A	4v01A-1rjbA: 33.1	4v01A-1rjbA: 45.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_A_0LIA1776_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 9	LEU A 616 VAL A 624 TYR A 693 CYH A 807 LEU A 818 ILE A 827	None	0.40A	4v01A-1rjbA: 33.1	4v01A-1rjbA: 45.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_B_0LIB1770_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	ALA A 642 GLU A 661 MET A 664 LEU A 802 HIS A 809 ASP A 829	None	0.93A	4v01B-1rjbA: 33.3	4v01B-1rjbA: 45.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_B_0LIB1770_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 9	LEU A 616 VAL A 624 LYS A 644 TYR A 693 LEU A 818 ILE A 827	None	0.63A	4v01B-1rjbA: 33.3	4v01B-1rjbA: 45.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V04_A_0LIA1772_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	VAL A 624 ALA A 642 GLU A 661 MET A 664 LEU A 802 CYH A 807	None	1.07A	4v04A-1rjbA: 32.8	4v04A-1rjbA: 45.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V04_A_0LIA1772_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	VAL A 624 ALA A 642 GLU A 661 MET A 664 LEU A 802 HIS A 809	None	0.90A	4v04A-1rjbA: 32.8	4v04A-1rjbA: 45.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V04_B_0LIB1771_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	ALA A 642 GLU A 661 MET A 664 LEU A 802 HIS A 809 ASP A 829	None	1.04A	4v04B-1rjbA: 33.4	4v04B-1rjbA: 45.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ZAU_A_YY3A1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 8	LEU A 616 GLY A 617 VAL A 624 ALA A 642 GLY A 697	None	0.66A	4zauA-1rjbA: 29.6	4zauA-1rjbA: 32.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_A_DB8A800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 ALA A 642 LYS A 644 CYH A 694 GLY A 697 LEU A 818 ASP A 829	None	1.35A	5ajqA-1rjbA: 21.6	5ajqA-1rjbA: 28.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_A_DB8A800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 GLY A 617 ALA A 642 CYH A 694 GLY A 697 LEU A 818 ASP A 829	None	0.93A	5ajqA-1rjbA: 21.6	5ajqA-1rjbA: 28.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_B_DB8B800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 10	ALA A 642 CYH A 694 GLY A 697 LEU A 818 ASP A 829	None	0.67A	5ajqB-1rjbA: 21.8	5ajqB-1rjbA: 28.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5BVW_A_1N1A1009_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 12	LEU A 616 VAL A 624 ALA A 642 LYS A 644 GLU A 661 TYR A 693 GLY A 697 LEU A 818	None	0.78A	5bvwA-1rjbA: 32.3	5bvwA-1rjbA: 31.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HI2_A_BAXA801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	ALA A 642 LYS A 644 GLU A 661 CYH A 694 LEU A 802 HIS A 809	None	0.76A	5hi2A-1rjbA: 27.7	5hi2A-1rjbA: 27.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HI2_A_BAXA801_2 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	4 / 8	VAL A 624 ILE A 674 ILE A 827 ASP A 829	None	0.61A	5hi2A-1rjbA: 27.7	5hi2A-1rjbA: 27.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5IZJ_F_AZ1F2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAR-DAR-DAR)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	4 / 7	GLY A 617 GLY A 619 GLY A 622 VAL A 624	None	0.30A	5izjB-1rjbA: 20.8	5izjB-1rjbA: 24.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5KR0_A_478A101_1 (PROTEASE E35D-APV)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 9	ALA A 792 ILE A 921 GLY A 875 ILE A 876 PRO A 911	None	1.03A	5kr0A-1rjbA: undetectable	5kr0A-1rjbA: 14.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2I_A_LQQA900_1 (CYCLIN-DEPENDENT KINASE 6)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	GLY A 617 VAL A 624 ALA A 642 VAL A 675 PHE A 691 ASP A 698 LEU A 818	None	0.60A	5l2iA-1rjbA: 6.6	5l2iA-1rjbA: 25.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	GLY A 617 VAL A 624 ALA A 642 VAL A 675 PHE A 691 ASP A 698 LEU A 818	None	0.86A	5l2tA-1rjbA: 6.6	5l2tA-1rjbA: 25.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LVN_A_ADNA402_1 (3-PHOSPHOINOSITIDE-D EPENDENT PROTEIN KINASE 1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 11	LEU A 616 GLY A 617 VAL A 624 ALA A 642 VAL A 675 TYR A 693 LEU A 818	None	0.47A	5lvnA-1rjbA: 21.9	5lvnA-1rjbA: 25.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MAF_A_XINA403_1 (MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	GLY A 617 VAL A 624 ALA A 642 LYS A 644 GLU A 661 TYR A 693 GLY A 697	None	0.71A	5mafA-1rjbA: 22.1	5mafA-1rjbA: 12.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OWR_A_1N1A401_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	4 / 8	ALA A 642 GLU A 661 CYH A 694 LEU A 818	None	0.48A	5owrA-1rjbA: 19.6	5owrA-1rjbA: 26.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5TE0_A_XINA401_2 (AP2-ASSOCIATED PROTEIN KINASE 1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	4 / 5	LEU A 616 VAL A 624 CYH A 694 CYH A 828	None	0.58A	5te0A-1rjbA: 21.8	5te0A-1rjbA: 23.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VC3_A_DB8A601_1 (WEE1-LIKE PROTEIN KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	GLY A 617 ALA A 642 GLU A 661 TYR A 693 CYH A 694 GLY A 697 ASP A 829	None	0.79A	5vc3A-1rjbA: 21.9	5vc3A-1rjbA: 24.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCV_A_1N1A404_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	LEU A 616 ALA A 642 GLU A 661 VAL A 675 LEU A 689 GLY A 697	None	1.09A	5vcvA-1rjbA: 21.9	5vcvA-1rjbA: 25.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCV_A_1N1A404_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	LEU A 616 ALA A 642 LYS A 644 GLU A 661 LEU A 689 GLY A 697	None	1.39A	5vcvA-1rjbA: 21.9	5vcvA-1rjbA: 25.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCY_A_DB8A401_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	LEU A 616 VAL A 624 ALA A 642 GLU A 661 LEU A 689 CYH A 694	None	0.70A	5vcyA-1rjbA: 21.6	5vcyA-1rjbA: 25.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCY_A_DB8A401_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	6 / 12	LEU A 616 VAL A 624 ALA A 642 LYS A 644 GLU A 661 LEU A 689	None	0.93A	5vcyA-1rjbA: 21.6	5vcyA-1rjbA: 25.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5W5V_A_ANWA701_0 (SERINE/THREONINE-PRO TEIN KINASE TBK1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 9	LEU A 616 ALA A 642 VAL A 675 CYH A 694 GLY A 697	None	0.49A	5w5vA-1rjbA: 13.4	5w5vA-1rjbA: 20.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5XV7_A_EMHA705_1 (SERINE-ARGININE (SR) PROTEIN KINASE 1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	5 / 12	LEU A 616 GLY A 617 VAL A 624 ALA A 642 PHE A 691	None	0.45A	5xv7A-1rjbA: 19.8	5xv7A-1rjbA: 12.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 VAL A 624 ALA A 642 GLU A 661 CYH A 694 GLY A 697 LEU A 818	None	0.57A	5y7zA-1rjbA: 21.1	5y7zA-1rjbA: 12.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 VAL A 624 ALA A 642 GLU A 661 CYH A 694 GLY A 697 LEU A 818	None	0.57A	5y7zA-1rjbA: 21.1	5y7zA-1rjbA: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_B_IREB401_0 (CYCLIN-G-ASSOCIATED KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 12	LEU A 616 ALA A 642 GLU A 661 CYH A 694 GLY A 697 LEU A 818 CYH A 828 ASP A 829	None	0.87A	5y7zB-1rjbA: 21.2	5y7zB-1rjbA: 12.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y80_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	8 / 12	LEU A 616 VAL A 624 ALA A 642 GLU A 661 CYH A 694 GLY A 697 LEU A 818 ASP A 829	None	0.75A	5y80A-1rjbA: 20.8	5y80A-1rjbA: 12.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y9M_A_NIOA401_1 (CASEIN KINASE II SUBUNIT ALPHA')	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	4 / 8	LEU A 616 VAL A 624 LYS A 644 PHE A 691	None	0.71A	5y9mA-1rjbA: 20.1	5y9mA-1rjbA: 16.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_A_LEVA801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 GLY A 617 VAL A 624 ALA A 642 GLU A 661 TYR A 693 GLY A 697	None	0.88A	5zv2A-1rjbA: 32.7	5zv2A-1rjbA: 15.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_B_LEVB801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 GLY A 617 VAL A 624 ALA A 642 LYS A 644 GLU A 661 GLY A 697	None	1.01A	5zv2B-1rjbA: 32.3	5zv2B-1rjbA: 15.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ECE_C_DVAC3010_0 (VLM2 DODECADEPSIPEPTIDE)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	3 / 3	ALA A 856 PHE A 928 GLN A 903	None	0.82A	6eceA-1rjbA: undetectable	6eceA-1rjbA: 21.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD6_B_STIB601_0 (TYROSINE-PROTEIN KINASE ABL1)	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	7 / 12	LEU A 616 VAL A 624 ALA A 642 GLU A 661 VAL A 675 LEU A 818 ASP A 829	None	0.85A	6hd6B-1rjbA: 32.3	6hd6B-1rjbA: 13.17

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1FMO_E_ADNE351_1","CAMP-DEPENDENT PROTEIN KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;VAL A 675;ASN A 816;LEU A 818","None","0.58A","1fmoE-1rjbA:20.2","1fmoE-1rjbA:25.06"],["1FMO_E_ADNE351_1","CAMP-DEPENDENT PROTEIN KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;VAL A 624;ALA A 642;VAL A 675;ASN A 816;LEU A 818;ASP A 829","None","0.62A","1fmoE-1rjbA:20.2","1fmoE-1rjbA:25.06"],["1MUO_A_ADNA1_1","AURORA-RELATED KINASE 1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;TYR A 693;LEU A 818","None","0.67A","1muoA-1rjbA:17.2","1muoA-1rjbA:27.40"],["1MXG_A_ACRA443_1","ALPHA AMYLASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",4,"SER A 941;THR A 940;ASN A 938;LYS A 868","None","1.20A","1mxgA-1rjbA:undetectable","1mxgA-1rjbA:22.12"],["1OPJ_A_STIA3_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;VAL A 675;LEU A 818","None","0.67A","1opjA-1rjbA:32.5","1opjA-1rjbA:35.85"],["1OPJ_B_STIB4_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"VAL A 624;ALA A 642;GLU A 661;VAL A 675;GLY A 697;ASP A 829","None","0.83A","1opjB-1rjbA:32.4","1opjB-1rjbA:35.85"],["1SGU_B_MK1B2632_1","POL POLYPROTEIN;POL POLYPROTEIN","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"ALA A 792;ILE A 921;GLY A 875;ILE A 876;PRO A 911","None","1.19A","1sguA-1rjbA:undetectable","1sguA-1rjbA:14.24"],["1SH9_B_RITB301_1","POL POLYPROTEIN;POL POLYPROTEIN","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"ALA A 792;ILE A 918;ILE A 921;GLY A 875;ILE A 876;PRO A 911","None","1.11A","1sh9A-1rjbA:undetectable","1sh9A-1rjbA:14.24"],["1T46_A_STIA3_1","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",9,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;GLU A 661;VAL A 675;GLY A 697;LEU A 818;ASP A 829","None","0.64A","1t46A-1rjbA:40.4","1t46A-1rjbA:58.77"],["1T46_A_STIA3_2","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",4,"TYR A 693;CYH A 694;CYH A 807;CYH A 828","None","0.48A","1t46A-1rjbA:40.4","1t46A-1rjbA:58.77"],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"ALA A 642;GLU A 661;CYH A 694;LEU A 802;HIS A 809","None","0.45A","1uwhA-1rjbA:28.1","1uwhA-1rjbA:26.59"],["1UWH_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"ALA A 642;LYS A 644;GLU A 661;CYH A 694;LEU A 802;HIS A 809","None","0.72A","1uwhB-1rjbA:27.8","1uwhB-1rjbA:26.59"],["1UWJ_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"VAL A 624;ALA A 642;GLU A 661;CYH A 694;LEU A 802;HIS A 809","None","0.51A","1uwjA-1rjbA:7.7","1uwjA-1rjbA:26.59"],["1UWJ_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"VAL A 624;ALA A 642;GLU A 661;CYH A 694;LEU A 802;HIS A 809","None","0.51A","1uwjB-1rjbA:7.7","1uwjB-1rjbA:26.59"],["2EUF_B_LQQB401_1","CELL DIVISION PROTEIN KINASE 6","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"VAL A 624;LYS A 644;VAL A 675;PHE A 691;ASP A 698;ASN A 816;LEU A 818;ASP A 829","None","0.91A","2eufB-1rjbA:22.4","2eufB-1rjbA:26.60"],["2HYY_A_STIA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"VAL A 624;ALA A 642;GLU A 661;GLY A 697;LEU A 818;ASP A 829","None","0.76A","2hyyA-1rjbA:33.5","2hyyA-1rjbA:37.91"],["2HYY_B_STIB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"VAL A 624;ALA A 642;GLU A 661;GLY A 697;LEU A 818;ASP A 829","None","0.78A","2hyyB-1rjbA:33.8","2hyyB-1rjbA:37.91"],["2O4N_A_TPVA300_1","PROTEASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"ALA A 792;ILE A 918;ILE A 921;GLY A 875;PRO A 911","None","0.93A","2o4nA-1rjbA:undetectable","2o4nA-1rjbA:14.83"],["2O4P_A_TPVA300_1","PROTEASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"ALA A 792;ILE A 921;GLY A 875;ILE A 876;PRO A 911","None","1.09A","2o4pA-1rjbA:undetectable","2o4pA-1rjbA:15.12"],["2YFX_A_VGHA9000_1","TYROSINE-PROTEIN KINASE RECEPTOR","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",4,"LEU A 616;ALA A 642;GLY A 697;LEU A 818","None","0.58A","2yfxA-1rjbA:29.3","2yfxA-1rjbA:36.68"],["3C7Q_A_XINA1172_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",9,"LEU A 616;GLY A 617;ALA A 642;LYS A 644;VAL A 675;CYH A 694;GLY A 697;LEU A 818;CYH A 828","None","0.60A","3c7qA-1rjbA:35.2","3c7qA-1rjbA:51.96"],["3EL4_A_ROCA100_2","PROTEASE;PROTEASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"ALA A 792;ILE A 921;GLY A 875;ILE A 876;PRO A 911","None","1.25A","3el4B-1rjbA:undetectable","3el4B-1rjbA:14.83"],["3EL5_B_1UNB201_1","PROTEASE;PROTEASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"ALA A 792;ILE A 921;GLY A 875;ILE A 876;PRO A 911","None","1.17A","3el5A-1rjbA:undetectable","3el5A-1rjbA:15.12"],["3FUP_B_MI1B1_1","TYROSINE-PROTEIN KINASE JAK2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;VAL A 675;TYR A 693;LEU A 818","None","0.53A","3fupB-1rjbA:27.7","3fupB-1rjbA:31.94"],["3G0E_A_B49A9000_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",10,"LEU A 616;VAL A 624;ALA A 642;VAL A 675;TYR A 693;CYH A 694;GLY A 697;LEU A 818;CYH A 828;ALA A 833","None","0.54A","3g0eA-1rjbA:41.8","3g0eA-1rjbA:56.77"],["3G0F_A_B49A9001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",9,"LEU A 616;VAL A 624;ALA A 642;TYR A 693;CYH A 694;GLY A 697;ASP A 698;LEU A 818;CYH A 828","None","0.55A","3g0fA-1rjbA:38.5","3g0fA-1rjbA:56.48"],["3G0F_B_B49B9001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;VAL A 624;ALA A 642;TYR A 693;CYH A 694;GLY A 697;LEU A 818;CYH A 828","None","0.48A","3g0fB-1rjbA:38.8","3g0fB-1rjbA:56.48"],["3G5D_B_1N1B1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",9,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;GLU A 661;VAL A 675;TYR A 693;GLY A 697;LEU A 818","None","0.94A","3g5dB-1rjbA:29.7","3g5dB-1rjbA:36.10"],["3GVU_A_STIA1001_1","TYROSINE-PROTEIN KINASE ABL2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;VAL A 675;LEU A 818;ASP A 829","None","0.82A","3gvuA-1rjbA:32.1","3gvuA-1rjbA:38.29"],["3IK3_A_0LIA1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"ALA A 642;GLU A 661;HIS A 809;LEU A 818;ASP A 829","None","0.68A","3ik3A-1rjbA:32.0","3ik3A-1rjbA:37.57"],["3K5V_A_STIA2_1","TYROSINE-PROTEIN KINASE ABL1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"VAL A 624;ALA A 642;GLU A 661;GLY A 697;LEU A 818;ASP A 829","None","0.76A","3k5vA-1rjbA:32.6","3k5vA-1rjbA:35.85"],["3KO0_C_TFPC201_1","PROTEIN S100-A4;PROTEIN S100-A4","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"PHE A 898;GLY A 891;ILE A 876;MET A 855;PHE A 861","None","1.49A","3ko0A-1rjbA:undetectable;3ko0C-1rjbA:undetectable","3ko0A-1rjbA:16.67;3ko0C-1rjbA:16.67"],["3MS9_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;GLY A 697;LEU A 818;ASP A 829","None","0.79A","3ms9B-1rjbA:33.4","3ms9B-1rjbA:35.85"],["3MSS_D_STID1_1","TYROSINE-PROTEIN KINASE ABL1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"LEU A 616;ALA A 642;GLU A 661;GLY A 697;LEU A 818;ASP A 829","None","0.76A","3mssD-1rjbA:33.5","3mssD-1rjbA:35.85"],["3NUO_B_478B478_1","PROTEASE;PROTEASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"ALA A 792;ILE A 921;GLY A 875;ILE A 876;PRO A 911","None","1.10A","3nuoA-1rjbA:undetectable","3nuoA-1rjbA:14.24"],["3OCT_A_1N1A663_1","TYROSINE-PROTEIN KINASE BTK","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;VAL A 675;TYR A 693;GLY A 697;LEU A 818","None","0.71A","3octA-1rjbA:29.8","3octA-1rjbA:36.36"],["3OCT_A_1N1A663_1","TYROSINE-PROTEIN KINASE BTK","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;VAL A 624;LYS A 644;MET A 665;VAL A 675;TYR A 693;GLY A 697;LEU A 818","None","1.00A","3octA-1rjbA:29.8","3octA-1rjbA:36.36"],["3OEZ_A_STIA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"ALA A 642;GLU A 661;VAL A 675;TYR A 693;GLY A 697;LEU A 818;ASP A 829","None","0.71A","3oezA-1rjbA:30.8","3oezA-1rjbA:35.82"],["3OXZ_A_0LIA1_1","TYROSINE-PROTEIN KINASE ABL1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"ALA A 642;GLU A 661;VAL A 675;GLY A 697;HIS A 809;ASP A 829","None","0.72A","3oxzA-1rjbA:31.7","3oxzA-1rjbA:37.72"],["3PYY_B_STIB4_1","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;VAL A 675;LEU A 818;ASP A 829","None","0.82A","3pyyB-1rjbA:31.1","3pyyB-1rjbA:35.88"],["3QLG_B_1N1B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;VAL A 675;TYR A 693;GLY A 697;LEU A 818","None","0.81A","3qlgB-1rjbA:29.7","3qlgB-1rjbA:35.82"],["3RGF_A_BAXA465_1","CYCLIN-DEPENDENT KINASE 8","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"VAL A 624;ALA A 642;GLU A 661;PHE A 691;TYR A 693;LEU A 802;HIS A 809","None","0.82A","3rgfA-1rjbA:20.3","3rgfA-1rjbA:27.33"],["3RGF_A_BAXA465_2","CYCLIN-DEPENDENT KINASE 8","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",4,"LEU A 818;VAL A 675;LEU A 668;ASP A 829","None","0.82A","3rgfA-1rjbA:20.3","3rgfA-1rjbA:27.33"],["3SXR_A_1N1A1_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;VAL A 624;ALA A 642;VAL A 675;TYR A 693;GLY A 697;LEU A 818","None","0.52A","3sxrA-1rjbA:29.1","3sxrA-1rjbA:36.07"],["3SXR_B_1N1B2_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;VAL A 624;ALA A 642;VAL A 675;TYR A 693;GLY A 697;LEU A 818","None","0.53A","3sxrB-1rjbA:28.9","3sxrB-1rjbA:36.07"],["3TI1_A_B49A299_1","CYCLIN-DEPENDENT KINASE 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"ALA A 642;VAL A 675;PHE A 691;ASP A 698;LEU A 818","None","0.71A","3ti1A-1rjbA:21.3","3ti1A-1rjbA:26.32"],["3U7S_A_017A201_2","POL POLYPROTEIN;POL POLYPROTEIN","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"ALA A 792;ILE A 921;GLY A 875;ILE A 876;PRO A 911","None","1.16A","3u7sB-1rjbA:undetectable","3u7sB-1rjbA:15.99"],["3WZD_A_LEVA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;GLU A 661;CYH A 694;CYH A 828","None","0.87A","3wzdA-1rjbA:33.7","3wzdA-1rjbA:48.27"],["3WZD_A_LEVA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;CYH A 694;GLY A 697;CYH A 828","None","0.58A","3wzdA-1rjbA:33.7","3wzdA-1rjbA:48.27"],["3WZE_A_BAXA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;GLU A 661;GLY A 697;LEU A 802;HIS A 809","None","0.60A","3wzeA-1rjbA:40.1","3wzeA-1rjbA:48.27"],["3WZE_A_BAXA1201_2","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"VAL A 675;CYH A 694;LEU A 818;ILE A 827;CYH A 828;ASP A 829","None","0.66A","3wzeA-1rjbA:40.1","3wzeA-1rjbA:48.27"],["3WZE_A_BAXA1201_2","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"VAL A 675;ILE A 827;CYH A 828;ASP A 829;PHE A 830","None","0.83A","3wzeA-1rjbA:40.1","3wzeA-1rjbA:48.27"],["3ZOS_A_0LIA1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;ALA A 642;LYS A 644;GLU A 661;HIS A 809;ARG A 810;LEU A 818;ASP A 829","None","0.87A","3zosA-1rjbA:32.8","3zosA-1rjbA:32.11"],["3ZOS_A_0LIA1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;ALA A 642;LYS A 644;GLU A 661;LEU A 802;HIS A 809;LEU A 818;ASP A 829","None","0.73A","3zosA-1rjbA:32.8","3zosA-1rjbA:32.11"],["3ZOS_B_0LIB1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"ALA A 642;LYS A 644;GLU A 661;LEU A 802;HIS A 809;LEU A 818;ASP A 829","None","0.72A","3zosB-1rjbA:33.0","3zosB-1rjbA:32.11"],["4AG8_A_AXIA2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",9,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;GLU A 661;VAL A 675;GLY A 697;LEU A 818;CYH A 828","None","0.53A","4ag8A-1rjbA:40.2","4ag8A-1rjbA:48.70"],["4AGC_A_AXIA2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;GLU A 661;GLY A 697;LEU A 818;CYH A 828","None","0.53A","4agcA-1rjbA:42.2","4agcA-1rjbA:47.80"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;ALA A 642;LYS A 644;VAL A 675;CYH A 694;GLY A 697;LEU A 818;CYH A 828","None","0.65A","4agdA-1rjbA:41.1","4agdA-1rjbA:47.80"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"LYS A 644;VAL A 675;GLY A 697;LEU A 818;CYH A 828;PHE A 830","None","1.26A","4agdA-1rjbA:41.1","4agdA-1rjbA:47.80"],["4ASD_A_BAXA1500_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;GLU A 661;GLY A 697;LEU A 802;HIS A 809","None","0.53A","4asdA-1rjbA:40.6","4asdA-1rjbA:47.80"],["4ASD_A_BAXA1500_2","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"VAL A 675;CYH A 694;LEU A 818;ILE A 827;CYH A 828","None","0.55A","4asdA-1rjbA:40.6","4asdA-1rjbA:47.80"],["4C8B_A_0LIA1000_2","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",4,"VAL A 624;ILE A 674;TYR A 693;ILE A 827","None","0.45A","4c8bA-1rjbA:25.5","4c8bA-1rjbA:25.85"],["4C8B_B_0LIB1000_1","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"ALA A 642;LYS A 644;GLU A 661;ILE A 674;HIS A 809;LEU A 818;ASP A 829","None","0.85A","4c8bB-1rjbA:25.3","4c8bB-1rjbA:25.85"],["4CKI_A_ADNA2022_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;TYR A 693;GLY A 697;LEU A 818","None","0.51A","4ckiA-1rjbA:30.8","4ckiA-1rjbA:42.77"],["4CKI_A_ADNA2022_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"LEU A 616;GLY A 831;ALA A 642;TYR A 693;GLY A 697;LEU A 818","None","0.67A","4ckiA-1rjbA:30.8","4ckiA-1rjbA:42.77"],["4CKJ_A_ADNA2014_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;GLY A 617;GLY A 619;VAL A 624;ALA A 642;TYR A 693;LEU A 818","None","0.55A","4ckjA-1rjbA:31.5","4ckjA-1rjbA:43.06"],["4IAA_A_RTZA401_1","SERINE\/THREONINE-PROTEIN KINASE PIM-1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"VAL A 624;ALA A 642;LYS A 644;ASP A 698;LEU A 818;ASP A 829","None","0.83A","4iaaA-1rjbA:20.4","4iaaA-1rjbA:24.86"],["4L9I_A_8PRA601_1","RHODOPSIN KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",4,"VAL A 624;ALA A 642;ASP A 698;LEU A 818","None","0.56A","4l9iA-1rjbA:7.8","4l9iA-1rjbA:22.27"],["4L9I_B_8PRB601_1","RHODOPSIN KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"VAL A 624;ALA A 642;LYS A 644;ASP A 698;LEU A 818","None","0.78A","4l9iB-1rjbA:20.2","4l9iB-1rjbA:22.27"],["4MKC_A_4MKA1503_1","ALK TYROSINE KINASE RECEPTOR","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;GLY A 697;ASP A 698;LEU A 818","None","0.55A","4mkcA-1rjbA:29.5","4mkcA-1rjbA:36.27"],["4O0W_A_ADNA501_1","AURORA KINASE A","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;LEU A 818","None","0.52A","4o0wA-1rjbA:22.8","4o0wA-1rjbA:26.30"],["4OGR_E_ADNE401_1","CYCLIN-DEPENDENT KINASE 9","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"ALA A 642;CYH A 694;ASP A 698;ASN A 816;LEU A 818;ASP A 829","None","0.88A","4ogrE-1rjbA:21.1","4ogrE-1rjbA:27.68"],["4OGR_E_ADNE401_1","CYCLIN-DEPENDENT KINASE 9","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"GLY A 617;ALA A 642;CYH A 694;ASP A 698;LEU A 818","None","0.94A","4ogrE-1rjbA:21.1","4ogrE-1rjbA:27.68"],["4OGR_I_ADNI401_1","CYCLIN-DEPENDENT KINASE 9","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"GLY A 831;ALA A 642;CYH A 694;ASP A 698;ASN A 816;LEU A 818","None","0.96A","4ogrI-1rjbA:21.0","4ogrI-1rjbA:27.68"],["4OGR_I_ADNI401_1","CYCLIN-DEPENDENT KINASE 9","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"GLY A 831;CYH A 694;ASP A 698;ASN A 816;LEU A 818;ASP A 829","None","1.05A","4ogrI-1rjbA:21.0","4ogrI-1rjbA:27.68"],["4OGR_I_ADNI401_1","CYCLIN-DEPENDENT KINASE 9","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"VAL A 624;ALA A 642;CYH A 694;ASP A 698;ASN A 816;LEU A 818","None","0.76A","4ogrI-1rjbA:21.0","4ogrI-1rjbA:27.68"],["4QRC_A_0LIA802_2","FIBROBLAST GROWTH FACTOR RECEPTOR 4","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",4,"LEU A 616;VAL A 624;HIS A 809;LEU A 818","None","0.37A","4qrcA-1rjbA:33.7","4qrcA-1rjbA:43.90"],["4R7I_A_STIA1001_1","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"VAL A 624;ALA A 642;LYS A 644;GLU A 661;CYH A 694;CYH A 807;LEU A 818","None","0.61A","4r7iA-1rjbA:39.9","4r7iA-1rjbA:55.78"],["4R7I_A_STIA1001_1","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"VAL A 624;ALA A 642;LYS A 644;GLU A 661;CYH A 694;LEU A 818;ASP A 829","None","0.59A","4r7iA-1rjbA:39.9","4r7iA-1rjbA:55.78"],["4TWP_A_AXIA601_1","TYROSINE-PROTEIN KINASE ABL1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;GLY A 697;ASN A 816;LEU A 818;ASP A 829","None","0.79A","4twpA-1rjbA:30.5","4twpA-1rjbA:37.50"],["4TYJ_A_0LIA801_2","FIBROBLAST GROWTH FACTOR RECEPTOR 4","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",4,"LEU A 616;VAL A 624;ILE A 674;ILE A 827","None","0.35A","4tyjA-1rjbA:33.4","4tyjA-1rjbA:43.60"],["4U0I_A_0LIA1001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;VAL A 624;GLU A 661;LEU A 668;ILE A 674;VAL A 675;TYR A 693;ILE A 827","None","0.78A","4u0iA-1rjbA:39.8","4u0iA-1rjbA:55.52"],["4U0I_A_0LIA1001_2","MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"ALA A 642;LYS A 644;CYH A 694;GLY A 697;HIS A 809;LEU A 818;CYH A 828;ASP A 829","None","0.64A","4u0iA-1rjbA:39.8","4u0iA-1rjbA:55.52"],["4U5J_A_RXTA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;VAL A 624;ALA A 642;TYR A 693;GLY A 697;ASN A 816;LEU A 818;ASP A 829","None","0.70A","4u5jA-1rjbA:30.3","4u5jA-1rjbA:36.10"],["4U5J_B_RXTB601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;VAL A 624;ALA A 642;TYR A 693;GLY A 697;LEU A 818;ASP A 829","None","0.93A","4u5jB-1rjbA:29.9","4u5jB-1rjbA:36.10"],["4UXQ_A_0LIA1752_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"LEU A 616;ALA A 642;GLU A 661;LEU A 802;HIS A 809;LEU A 818","None","0.62A","4uxqA-1rjbA:34.2","4uxqA-1rjbA:43.90"],["4V01_A_0LIA1776_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"ALA A 642;GLU A 661;MET A 664;LEU A 802;HIS A 809;ASP A 829","None","0.98A","4v01A-1rjbA:33.1","4v01A-1rjbA:45.95"],["4V01_A_0LIA1776_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"LEU A 616;VAL A 624;TYR A 693;CYH A 807;LEU A 818;ILE A 827","None","0.40A","4v01A-1rjbA:33.1","4v01A-1rjbA:45.95"],["4V01_B_0LIB1770_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"ALA A 642;GLU A 661;MET A 664;LEU A 802;HIS A 809;ASP A 829","None","0.93A","4v01B-1rjbA:33.3","4v01B-1rjbA:45.95"],["4V01_B_0LIB1770_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"LEU A 616;VAL A 624;LYS A 644;TYR A 693;LEU A 818;ILE A 827","None","0.63A","4v01B-1rjbA:33.3","4v01B-1rjbA:45.95"],["4V04_A_0LIA1772_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"VAL A 624;ALA A 642;GLU A 661;MET A 664;LEU A 802;CYH A 807","None","1.07A","4v04A-1rjbA:32.8","4v04A-1rjbA:45.95"],["4V04_A_0LIA1772_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"VAL A 624;ALA A 642;GLU A 661;MET A 664;LEU A 802;HIS A 809","None","0.90A","4v04A-1rjbA:32.8","4v04A-1rjbA:45.95"],["4V04_B_0LIB1771_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"ALA A 642;GLU A 661;MET A 664;LEU A 802;HIS A 809;ASP A 829","None","1.04A","4v04B-1rjbA:33.4","4v04B-1rjbA:45.95"],["4ZAU_A_YY3A1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;GLY A 697","None","0.66A","4zauA-1rjbA:29.6","4zauA-1rjbA:32.38"],["5AJQ_A_DB8A800_1","SERINE\/THREONINE-PROTEIN KINASE 10","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;ALA A 642;LYS A 644;CYH A 694;GLY A 697;LEU A 818;ASP A 829","None","1.35A","5ajqA-1rjbA:21.6","5ajqA-1rjbA:28.33"],["5AJQ_A_DB8A800_1","SERINE\/THREONINE-PROTEIN KINASE 10","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;GLY A 617;ALA A 642;CYH A 694;GLY A 697;LEU A 818;ASP A 829","None","0.93A","5ajqA-1rjbA:21.6","5ajqA-1rjbA:28.33"],["5AJQ_B_DB8B800_1","SERINE\/THREONINE-PROTEIN KINASE 10","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"ALA A 642;CYH A 694;GLY A 697;LEU A 818;ASP A 829","None","0.67A","5ajqB-1rjbA:21.8","5ajqB-1rjbA:28.33"],["5BVW_A_1N1A1009_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;GLU A 661;TYR A 693;GLY A 697;LEU A 818","None","0.78A","5bvwA-1rjbA:32.3","5bvwA-1rjbA:31.51"],["5HI2_A_BAXA801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"ALA A 642;LYS A 644;GLU A 661;CYH A 694;LEU A 802;HIS A 809","None","0.76A","5hi2A-1rjbA:27.7","5hi2A-1rjbA:27.53"],["5HI2_A_BAXA801_2","SERINE\/THREONINE-PROTEIN KINASE B-RAF","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",4,"VAL A 624;ILE A 674;ILE A 827;ASP A 829","None","0.61A","5hi2A-1rjbA:27.7","5hi2A-1rjbA:27.53"],["5IZJ_F_AZ1F2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAR-DAR-DAR","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",4,"GLY A 617;GLY A 619;GLY A 622;VAL A 624","None","0.30A","5izjB-1rjbA:20.8","5izjB-1rjbA:24.69"],["5KR0_A_478A101_1","PROTEASE E35D-APV","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"ALA A 792;ILE A 921;GLY A 875;ILE A 876;PRO A 911","None","1.03A","5kr0A-1rjbA:undetectable","5kr0A-1rjbA:14.24"],["5L2I_A_LQQA900_1","CYCLIN-DEPENDENT KINASE 6","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"GLY A 617;VAL A 624;ALA A 642;VAL A 675;PHE A 691;ASP A 698;LEU A 818","None","0.60A","5l2iA-1rjbA:6.6","5l2iA-1rjbA:25.86"],["5L2T_A_6ZZA900_1","CYCLIN-DEPENDENT KINASE 6","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"GLY A 617;VAL A 624;ALA A 642;VAL A 675;PHE A 691;ASP A 698;LEU A 818","None","0.86A","5l2tA-1rjbA:6.6","5l2tA-1rjbA:25.86"],["5LVN_A_ADNA402_1","3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;VAL A 675;TYR A 693;LEU A 818","None","0.47A","5lvnA-1rjbA:21.9","5lvnA-1rjbA:25.88"],["5MAF_A_XINA403_1","MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"GLY A 617;VAL A 624;ALA A 642;LYS A 644;GLU A 661;TYR A 693;GLY A 697","None","0.71A","5mafA-1rjbA:22.1","5mafA-1rjbA:12.42"],["5OWR_A_1N1A401_1","SERINE\/THREONINE-PROTEIN KINASE 10","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",4,"ALA A 642;GLU A 661;CYH A 694;LEU A 818","None","0.48A","5owrA-1rjbA:19.6","5owrA-1rjbA:26.46"],["5TE0_A_XINA401_2","AP2-ASSOCIATED PROTEIN KINASE 1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",4,"LEU A 616;VAL A 624;CYH A 694;CYH A 828","None","0.58A","5te0A-1rjbA:21.8","5te0A-1rjbA:23.04"],["5VC3_A_DB8A601_1","WEE1-LIKE PROTEIN KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"GLY A 617;ALA A 642;GLU A 661;TYR A 693;CYH A 694;GLY A 697;ASP A 829","None","0.79A","5vc3A-1rjbA:21.9","5vc3A-1rjbA:24.44"],["5VCV_A_1N1A404_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"LEU A 616;ALA A 642;GLU A 661;VAL A 675;LEU A 689;GLY A 697","None","1.09A","5vcvA-1rjbA:21.9","5vcvA-1rjbA:25.34"],["5VCV_A_1N1A404_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"LEU A 616;ALA A 642;LYS A 644;GLU A 661;LEU A 689;GLY A 697","None","1.39A","5vcvA-1rjbA:21.9","5vcvA-1rjbA:25.34"],["5VCY_A_DB8A401_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;LEU A 689;CYH A 694","None","0.70A","5vcyA-1rjbA:21.6","5vcyA-1rjbA:25.34"],["5VCY_A_DB8A401_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",6,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;GLU A 661;LEU A 689","None","0.93A","5vcyA-1rjbA:21.6","5vcyA-1rjbA:25.34"],["5W5V_A_ANWA701_0","SERINE\/THREONINE-PROTEIN KINASE TBK1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"LEU A 616;ALA A 642;VAL A 675;CYH A 694;GLY A 697","None","0.49A","5w5vA-1rjbA:13.4","5w5vA-1rjbA:20.97"],["5XV7_A_EMHA705_1","SERINE-ARGININE (SR) PROTEIN KINASE 1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",5,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;PHE A 691","None","0.45A","5xv7A-1rjbA:19.8","5xv7A-1rjbA:12.57"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;CYH A 694;GLY A 697;LEU A 818","None","0.57A","5y7zA-1rjbA:21.1","5y7zA-1rjbA:12.82"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;CYH A 694;GLY A 697;LEU A 818","None","0.57A","5y7zA-1rjbA:21.1","5y7zA-1rjbA:24.93"],["5Y7Z_B_IREB401_0","CYCLIN-G-ASSOCIATED KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;ALA A 642;GLU A 661;CYH A 694;GLY A 697;LEU A 818;CYH A 828;ASP A 829","None","0.87A","5y7zB-1rjbA:21.2","5y7zB-1rjbA:12.82"],["5Y80_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",8,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;CYH A 694;GLY A 697;LEU A 818;ASP A 829","None","0.75A","5y80A-1rjbA:20.8","5y80A-1rjbA:12.82"],["5Y9M_A_NIOA401_1","CASEIN KINASE II SUBUNIT ALPHA'","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",4,"LEU A 616;VAL A 624;LYS A 644;PHE A 691","None","0.71A","5y9mA-1rjbA:20.1","5y9mA-1rjbA:16.36"],["5ZV2_A_LEVA801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;GLU A 661;TYR A 693;GLY A 697","None","0.88A","5zv2A-1rjbA:32.7","5zv2A-1rjbA:15.06"],["5ZV2_B_LEVB801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;LYS A 644;GLU A 661;GLY A 697","None","1.01A","5zv2B-1rjbA:32.3","5zv2B-1rjbA:15.06"],["6ECE_C_DVAC3010_0","VLM2;DODECADEPSIPEPTIDE","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",3,"ALA A 856;PHE A 928;GLN A 903","None","0.82A","6eceA-1rjbA:undetectable","6eceA-1rjbA:21.25"],["6HD6_B_STIB601_0","TYROSINE-PROTEIN KINASE ABL1","1rjb","FL CYTOKINE RECEPTOR","Homo sapiens",7,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;VAL A 675;LEU A 818;ASP A 829","None","0.85A","6hd6B-1rjbA:32.3","6hd6B-1rjbA:13.17"]]